Gene · 5106
PCK2: phosphoenolpyruvate carboxykinase 2, mitochondrial
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. PCK2: phosphoenolpyruvate carboxykinase 2, mitochondrial. Genes, record 5106. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/5106
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| Q16822 | Phosphoenolpyruvate carboxykinase [GTP], mitochondrial | 640 | 0 | Ensembl, GeneID, HGNC |
Source UniProt
Patents7
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| EP 4650780 A2 | 2025-11-19 | 366 | Q16822 | Espacenet |
| EP 4641201 A2 | 2025-10-29 | 261 | Q16822 | Espacenet |
| JP 2025517969 A | 2025-06-12 | 261 | Q16822 | Espacenet |
| JP 2025517970 A | 2025-06-12 | 366 | Q16822 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 63024 | Q16822 | Espacenet |
| JP 2022524081 A | 2022-04-27 | 165995 | Q16822 | Espacenet |
| US 7842467 B1 | 2010-11-30 | 2814 | Q16822 | Espacenet |
Drugs0
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
None in this release.
Trials0
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
None in this release.
NIH grants1,645
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | PCK2 papers | Newest fiscal year |
|---|---|---|---|
| P30DK045735 | Yale Diabetes Research Center | 13 | 2025 |
| P30DK020593 | Vanderbilt Diabetes Research Center | 12 | 2025 |
| T32DK007061 | Research Training in Diabetes and Endocrinology | 7 | 2025 |
| P30DK019525 | University of Pennsylvania Diabetes Research Center | 6 | 2025 |
| P01CA120964 | Molecular Pathogenesis of the Hamartoma Syndromes | 5 | 2025 |
| P30DK020541 | NYR-Diabetes Research Center (NYR-DRC) | 5 | 2025 |
| P30DK034989 | Yale Liver Center | 5 | 2025 |
| P30DK036836 | Diabetes Research Center | 5 | 2025 |
| R01DK078184 | Factors Controlling Metabolic Flux in the Liver | 5 | 2025 |
| UL1TR001863 | Yale Clinical and Translational Science Award | 5 | 2025 |
1 to 10 of 1,645Source NIH's project files
See all 1,645 nih grantsPapers3,204
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Structural characterization and insulin resistance-improving activity of glucomannogalactan from Volvariella volvacea. | Int J Biol Macromol | 2026 | 42826778 | PubTator, text mining | PubMed |
| Glycolytic reprogramming and cell-specific lactylation in asthma: an evidence-graded framework for testable metabolic-epigenetic profiles. | Front Immunol | 2026 | 42813062 | PubTator, text mining | PubMed |
| Crosstalk between NUAK1 and the SETD1A complex regulates glycolysis and gluconeogenesis upon glucose deprivation. | J Biol Chem | 2026 | 42778105 | PubTator, text mining | PubMed |
| Enterobacteriaceae for succinic acid biomanufacturing: metabolic blueprints, systems-level engineering and future perspectives. | Biotechnol Adv | 2026 | 42772475 | PubTator, text mining | PubMed |
| Targeting PCK2 alleviates GERD by suppressing MAPK-dependent endoplasmic reticulum stress and oxidative stress-induced apoptosis. | Biochim Biophys Acta Gen Subj | 2026 | 42692205 | PubTator, text mining | PubMed |
| Oxaloacetate damages mitochondria by perturbing MIC60-dependent membrane remodeling. | PLoS Biol | 2026 | 42664297 | PubTator, text mining | PubMed |
| PCK2 Inhibition Reverses Cisplatin Resistance of Non-Small Cell Lung Cancer by Triggering Ferroptosis. | FASEB J | 2026 | 42599961 | PubTator, text mining | PubMed |
| Docking Analysis of Drugs Used in the Treatment of Alzheimer's Disease, Using Cell Membrane Receptors and Enzymes of the Kynurenine Pathway: A Pilot Study. | Int J Mol Sci | 2026 | 42589213 | PubTator, text mining | PubMed |
| Circadian Regulation of Glucose Metabolism: Implications for Pathogenesis and Chronotherapy of Type 2 Diabetes. | Diabetology (Basel) | 2026 | 42583078 | PubTator, text mining | PubMed |
Metformin's disruption of gluconeogenesis in type 2 diabetes impairments of the cori and alanine cycles as hidden drivers of metabolic waste accumulation, NF-κBHIF-1α-mediated low-grade inflammation, and multisystem dysfunction. | Probl Endokrinol (Mosk) | 2026 | 42545322 | PubTator, text mining | PubMed |
1 to 10 of 3,204
See all 3,204 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/5106
GET https://conductscience.org/api/genes/v1/5106/grants?page=2